May 14 |
Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation
|
May 13 |
Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
|
May 13 |
Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
|
May 10 |
Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates
|
May 7 |
Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024
|
May 2 |
Mustang Bio Announces Closing of $4 Million Public Offering
|
May 1 |
Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer
|
Apr 30 |
Mustang Bio Announces Pricing of $4 Million Public Offering
|
Apr 29 |
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
|
Apr 25 |
Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024
|